Memorial Hospital Research Laboratories

The Adam Schmitt Lab

Share
Back to top

Research

Adam Schmitt
Adam Schmitt, MD

Until recently, the vast majority of the noncoding genome was thought be nonfunctional. Thanks to the rapid development of functional genomics, we now know that the noncoding genome is packed with a diverse array of noncoding RNAs and gene regulatory elements. Indeed, it is estimated that more than 80 percent of the genome contains biologically functional sequence, including thousands of long noncoding RNAs.

I am especially interested in how long noncoding RNAs control cellular behavior in response to stressors such as DNA damage and oncogene expression. My laboratory uses a combination of biochemistry, cellular biology, mouse genetics, and functional genomics to identify and characterize long noncoding RNAs involved in these processes.

The Adam Schmitt Lab

Publications Highlights

Yu AF, Moore ZR, Moskowitz CS, Liu JE, Dang CT, Ramanathan L, Oeffinger KC, Steingart RM, Schmitt AM. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer. JAMA Cardiol. 2023 Jul 1;8(7):697-702. doi: 10.1001/jamacardio.2023.1229. PubMed PMID: 37256614; PubMed Central PMCID: PMC10233452.

Shamseddine A, Patel SH, Chavez V, Moore ZR, Adnan M, Di Bona M, Li J, Dang CT, Ramanathan LV, Oeffinger KC, Liu JE, Steingart RM, Piersigilli A, Socci ND, Chan AT, Yu AF, Bakhoum SF, Schmitt AM. Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies. J Exp Med. 2023 Mar 6;220(3). doi: 10.1084/jem.20220809. Epub 2022 Dec 19. PubMed PMID: 36534085; PubMed Central PMCID: PMC9767651.

Peng KL, Vasudevan HN, Lockney DT, Baum R, Hendrickson RC, Raleigh DR, Schmitt AM. Miat and interacting protein Metadherin maintain a stem-like niche to promote medulloblastoma tumorigenesis and treatment resistance. Proc Natl Acad Sci U S A. 2022 Sep 13;119(37):e2203738119. doi: 10.1073/pnas.2203738119. Epub 2022 Sep 6. PubMed PMID: 36067288; PubMed Central PMCID: PMC9478675.

Marney CB, Anderson ES, Baum R, Schmitt AM. A Unique Spectrum of Spontaneous Tumors in Dino Knockout Mice Identifies Tissue-Specific Requirements for Tumor Suppression. Cells. 2022 Jun 2;11(11). doi: 10.3390/cells11111818. PubMed PMID: 35681513; PubMed Central PMCID: PMC9180304.

Marney CB, Anderson ES, Adnan M, Peng KL, Hu Y, Weinhold N, Schmitt AM. p53-intact cancers escape tumor suppression through loss of long noncoding RNA Dino. Cell Rep. 2021 Jun 29;35(13):109329. doi: 10.1016/j.celrep.2021.109329. PubMed PMID: 34192538; PubMed Central PMCID: PMC8287872.

View All Publications

People

Adam Schmitt

Adam Schmitt, MD

  • Physician-scientist Adam Schmitt studies how long noncoding RNAs regulate cellular stress responses and tumor development.
schmitta@mskcc.org
Email Address
View physician profile
Physician profile

Members

Mutayyaba Adnan

Research Technician

Erik Anderson

Radiation Oncology Resident

Christina Marney

Research Scholar

Suchit Patel

Radiation Oncology Resident

Kai-lin Peng

Research Fellow

Adam Schmitt
Lab Affiliations

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Adam Schmitt discloses the following relationships and financial interests:

  • Arinale Biosciences
    Equity; Fiduciary Role / Position; Intellectual Property Rights

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures